18FDG PET scanning of benign and malignant musculoskeletal lesions

Skeletal Radiology

Volumn 32, Issue 4, 2003, Pages 201-208

  Feldman, Frieda ^a,b   van Heertum, Ronald ^a,b   Manos, Chitra ^b  

^a Columbia Univ Coll Physicians/Surg ^*  (United States)

^b NEW YORK PRESBYTERIAN HOSPITAL   (United States)

Author keywords

18FDG PET; Musculoskeletal lesions

Indexed keywords

FLUORODEOXYGLUCOSE F 18; DIAGNOSTIC AGENT; RADIOPHARMACEUTICAL AGENT;

ADOLESCENT; ADULT; AGED; ARTICLE; BONE BIOPSY; BONE CANCER; BONE METABOLISM; BONE RADIOGRAPHY; BONE SCINTISCANNING; BONE TUMOR; CHILD; CLINICAL ARTICLE; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; DATA ANALYSIS; DIAGNOSTIC ACCURACY; DIAGNOSTIC PROCEDURE; DIFFERENTIAL DIAGNOSIS; FEMALE; HUMAN; IMAGE ANALYSIS; IMAGE RECONSTRUCTION; IMAGING SYSTEM; MALE; MEDICAL DECISION MAKING; MEDICAL DOCUMENTATION; METASTASIS; NUCLEAR MAGNETIC RESONANCE IMAGING; ORTHOPEDIC SURGERY; PATIENT CARE; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PROGNOSIS; SENSITIVITY AND SPECIFICITY; SURVIVAL; COMPUTER ASSISTED EMISSION TOMOGRAPHY; METHODOLOGY; MIDDLE AGED; SARCOMA; SCINTISCANNING; SOFT TISSUE TUMOR;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; BONE NEOPLASMS; CHILD; DIAGNOSIS, DIFFERENTIAL; FEMALE; FLUORODEOXYGLUCOSE F18; HUMANS; MALE; MIDDLE AGED; RADIOPHARMACEUTICALS; SARCOMA; SENSITIVITY AND SPECIFICITY; SOFT TISSUE NEOPLASMS; TOMOGRAPHY, EMISSION-COMPUTED;

EID: 0037844874     PISSN: 03642348     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00256-003-0623-3     Document Type: Article

References (29)

1. Blau M, Nagler W, Bender MA. Fluorine- 18 a new isotope for bone scanning. J Nucl Med 1962; 3:332-334.
2. Som P, Atkins, HL, Bandaypadhyay D, et al. A fluorinated glucose analog, 2-fluoro-2-glucose (F18): nontoxic tracer for rapid tumor detection. J Nucl Med 1980; 21:670-675.
3. Warburg O. The metabolism of tumors. London: Constable, 1930:75-327.
4. Schulte M, Brecht-Krauss D, Heymer B, et al. Grading of tumors and tumor-like lesions of bone: evaluation by FDG PET. J Nucl Med. 2000; 41:1695-1701.
5. Aoki J, Watanabe H, Shinozaki T, et al. FDG PET of primary benign and malignant bone tumors: standardized uptake value in 52 lesions. Radiology 2001; 219:774-777.
6. 18F PET. J Nucl Med. 1999;40:1623-1629.
7. Sasaki M, Ichiya Y, Kuwabara Y, et al. Fluorine- 18 fluorodeoxglucose positron emission tomography in technetium 99m hydroxymethylenediphosphate negative bone tumors. J Nucl Med 1993; 34:288-290.
8. Garcia R, Kim EE, Wong FC, et al. Comparison of fluorine-18 FDG PET and technetium-99m-MIBI SPECT in evaluation of musculoskeletal sarcomas. J Nucl Med 1996; 37:1476-1479.
9. Abdel-Dayem HM. The role of nuclear medicine in primary bone and soft tissue tumors. Semin Nucl Med. 1997; 27:355-363.
10. Kole AC, Nieweg OE, VanGinkel RJ, Pruim J, et al. Detection of local recurrence of soft-tissue sarcoma with positron emission tomography using 18-F fluorodeoxyglucose. Ann Surg Oncol 1997; 4:57-63.
11. Schwartzbach M, Willeke F, Dimitrakopoulou-Strauss A, et al. Functional imaging and detection of local recurrence in soft tissue sarcomas by position emission tomography. Anticancer Res 1999; 19:1343-1350.
12. Kern KA, Brunetti A, Nortn JA, et al. Metabolic imaging of human extremity musculoskeletal tumors by PET. J Nucl Med 1988; 29:181-186.
13. Kole AC, Nieweg OE, Hoekstra HJ, et al. Fluorine-18 fluorodeoxyglucose assessment of glucose metabolism in bone tumors. J Nucl Med 1998; 39:810-815.
14. 18F)FDG. J Comput Assist Tomogr 1990; 14:960-962.
15. Adler LP, Blair HF, Makley JT, et al. Noninvasive grading of musculoskeletal tumors using PET. J Nucl Med 1991; 32:1508-1512.
16. Nieweg OE, Pruim J, VanGinkle RJ, et al. Fluorine-18 fluorodeoxyglucose PET imaging of soft tissue sarcoma. J Nucl Med 1996; 37:257-261.
17. Griffeth LK, Dehdashti FD, McGire AH, et al. PET evaluation of soft-tissue masses with fluorine- 18 fluoro-2deoxy-D-glucose. Radiology 1992; 182:185-194.
18. Lodge MA, Lucas JD, Marsken PK, et al. A PET study: 18-FDG uptake in soft tissue masses. Eur J Nucl Med 1999; 26:22-30.
19. Lucas JD, O'Doherthy MJ, Wong JC, et al. Evaluation of fluorodeoxyglucose positron emmision tomography in the management of soft tissue sarcomas. J Bone Joint Surg Br 1998; 80:441-447.
20. 18F)fluorodeoxyglucose positron emission tomography imaging in soft tissue sarcomas. Ann Surg 2002; 231:380-386.
21. Eary JF, Conrad E, Bruckner JD, et al. Quantitative (F-18)fluorodeoxyglucose position emission tomography in pretreatment and grading of sarcoma. Clin Cancer Res 1998; 4:1215-1220.
22. Brudin LH, Valid SO, Rhodes CG, et al. Fluorine- 18 deoxyglucose uptake in sarcoidosis measured with positron emission tomography. Eur J Nucl Med 1994; 21:297-305.
23. Kubota R, Yamada S, Kubota K, et al. Intratumoral distribution of fluorine18-fluorodeoxyglucose in vivo: high accumulation in macrophages and granulation tissue studies by microautoradiography. J Nucl Med 1992; 33:1972-1980.
24. Guhlmann A, Brechy-Krauss D, Suger G, et al. Chronic osteomyelitis: detection with FDG PET and correlation with histopathologic findings. Radiology 1998; 206:749-754.
25. Gamelli RL, Liu H, He L, et al. Augmentation of glucose transporter-1 in macrophages following thermal injury and sepsis in mice. J Leukoc Biol 1996; 59:639-647.
26. Dehdashti FD, Siegel GA, Griffeth LK, et al. Benign versus malignant intraosseous lesions: discrimination by means of PET with 2-(F-18)fluoro-2-deoxy-D-glucose. Radiology 1996; 200:243-247.
27. Zasadny KR, Wahl RL. Standardized uptake values of normal tissues at PET with 2-(fluorine-18)-fluoro-2-deoxy-D-glucose: variations with body weight and a method for correction. Radiology 1993; 189:847-850.
28. Hamberg LM, Hunter GJ, Alpert NM, et al. The dose uptake ratio as an index of glucose metabolism: useful parameter of oversimplification. J Nucl Med 1994; 35:1308-1312.
29. Wahl RL, Quint LE, Cieslak D, et al. Anatometabolic tumor imaging: fusion of FDG PET with CT or MRI to localize foci of increased activity. J Nucl Med 1993; 34:1190-1197.